They do have some legitimate products.
But they are too small to execute the type of trials needed to move these through to approval. Time is a precious resource and they need to move faster and with larger/broader trials.
I think Erlich and Menon want total control and with that in mind this company will take years to do anything of note.
Overall Fraz I have to agree...these are decent results. I think the "final dose" is a ways off and more trials are needed hence the minor sell off.
But if the results are better than Otezla and they seem to be...they have an active compound.
This company really needs a partnership and fast. The leadership/management is really lacking basic know how in getting these trials done. And they could use some $$$ to achieve that goal.
I think people wanted PASI scores in the 70-90% range.
I hate the way he puts results out there. Just shut up and post the numbers.
Still, this sounds similar to Otezla (Apremilast) but without the side effects.
IL12, IL23, IL17....IL6....
There are many cytokines implicated in psoriasis.
I hate waiting for results like this.
More often than not they are unimpressive or flat out negative. Hopefully CTIX bucks that trend. I have built a very small position over the past few weeks...we shall see.
Management is actually quite good.
I wish they'd pay a dividend no matter how small. The macroenvironment will hold them back but they have done well through tough times.
Not sure I read the part where it is for "mild" disease. If you have mild disease, take a cream. Moderate to severe...and creams fall short.